LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 48

Search options

  1. Article: Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.

    Rassi, Fuad El / Khoury, Hanna Jean

    Pharmacogenomics and personalized medicine

    2013  Volume 6, Page(s) 57–62

    Abstract: Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as ... ...

    Abstract Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through quality-of-life data. Bosutinib has shown considerable and sustained efficacy in chronic myeloid leukemia, especially in the chronic phase, with resistance or intolerance to prior tyrosine kinase inhibitors. Bosutinib has distinct but manageable adverse events. In the absence of T315I and V299L mutations, there are no absolute contraindications for the use of bosutinib in this patient population.
    Language English
    Publishing date 2013-08-05
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2508173-1
    ISSN 1178-7066
    ISSN 1178-7066
    DOI 10.2147/PGPM.S32145
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Updated product label allows home administration of omacetaxine mepesuccinate.

    Shen, Ann Q / Munteanu, Mihaela / Khoury, Hanna Jean

    The oncologist

    2014  Volume 19, Issue 11, Page(s) e14

    MeSH term(s) Angiogenesis Inhibitors/therapeutic use ; Female ; Harringtonines/therapeutic use ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Male
    Chemical Substances Angiogenesis Inhibitors ; Harringtonines
    Language English
    Publishing date 2014-10-03
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2014-0230
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.

    Khoury, Hanna Jean / Williams, Loretta A / Atallah, Ehab / Hehlmann, Rüdiger

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2017  Volume 37, Page(s) 468–479

    Abstract: The prognosis of chronic phase chronic myeloid leukemia (CML) has improved so that life expectancy for patients responding to tyrosine kinase inhibitors (TKIs) is now equivalent to age-matched controls. Attention should be paid to comorbidities that ... ...

    Abstract The prognosis of chronic phase chronic myeloid leukemia (CML) has improved so that life expectancy for patients responding to tyrosine kinase inhibitors (TKIs) is now equivalent to age-matched controls. Attention should be paid to comorbidities that impact survival. The success of TKI therapy can be easily and reliably assessed at well-accepted time points using quantitative polymerase chain reaction (PCR) standardized to the international scale. Patient-reported outcome (PRO) tools are readily available for use in the clinic and provide complementary information on the tolerance of TKIs. Effectively managing adverse events of TKIs can improve compliance and quality of life. Discontinuation of TKIs is the next frontier in CML. In select patients with sustained deep molecular remission, a discontinuation of TKI is associated with a durable treatment-free remission in approximately 50%. Patient engagement in their discontinuation can be achieved through a provider multi-team coaching, is complementary to the available guidelines, and may provide an additional safety net so that these discontinuations remain safe when applied in general practices.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Disease Management ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Medical Oncology/trends ; Prognosis ; Protein Kinase Inhibitors/therapeutic use ; Remission Induction ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Protein Kinase Inhibitors
    Language English
    Publishing date 2017-08-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.14694/EDBK_175712
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Management of advanced-phase chronic myeloid leukemia.

    DeFilipp, Zachariah / Khoury, Hanna Jean

    Current hematologic malignancy reports

    2015  Volume 10, Issue 2, Page(s) 173–181

    Abstract: The management of chronic myeloid leukemia (CML) in accelerated or blast phase (advanced phase) remains a significant challenge despite the introduction of very effective tyrosine kinase inhibitors (TKIs). The biology of advanced-phase CML is complex and ...

    Abstract The management of chronic myeloid leukemia (CML) in accelerated or blast phase (advanced phase) remains a significant challenge despite the introduction of very effective tyrosine kinase inhibitors (TKIs). The biology of advanced-phase CML is complex and engages several pathways that are not optimally targeted by TKIs. Allogeneic stem cell transplantation remains the only potentially curative therapy, but the effectiveness of this conventional approach is limited. New strategies are required to improve the outlook for these patients.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Blast Crisis/therapy ; Consolidation Chemotherapy/methods ; Disease Management ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Leukemia, Myeloid, Chronic-Phase/pathology ; Leukemia, Myeloid, Chronic-Phase/therapy ; Molecular Targeted Therapy/methods ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Antineoplastic Agents ; Protein Kinase Inhibitors
    Language English
    Publishing date 2015-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2229765-0
    ISSN 1558-822X ; 1558-8211
    ISSN (online) 1558-822X
    ISSN 1558-8211
    DOI 10.1007/s11899-015-0249-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6332: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

    Rosshandler, Yasmin / Shen, Ann Q / Cortes, Jorge / Khoury, Hanna Jean

    Expert review of hematology

    2016  Volume 9, Issue 5, Page(s) 419–424

    Abstract: Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the ... ...

    Abstract Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
    MeSH term(s) Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents, Phytogenic/chemistry ; Antineoplastic Agents, Phytogenic/pharmacology ; Antineoplastic Agents, Phytogenic/therapeutic use ; Blast Crisis/drug therapy ; Codon ; Fusion Proteins, bcr-abl/antagonists & inhibitors ; Fusion Proteins, bcr-abl/genetics ; Harringtonines/chemistry ; Harringtonines/pharmacology ; Harringtonines/therapeutic use ; Homoharringtonine ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Leukemia, Myeloid, Accelerated Phase/drug therapy ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Mutation ; Treatment Outcome
    Chemical Substances Angiogenesis Inhibitors ; Antineoplastic Agents, Phytogenic ; BCR-ABL1 fusion protein, human ; Codon ; Harringtonines ; Homoharringtonine (6FG8041S5B) ; Fusion Proteins, bcr-abl (EC 2.7.10.2)
    Language English
    Publishing date 2016-04-21
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1586/17474086.2016.1151351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6943: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

    Hill, Brittany G / Kota, Vamsi K / Khoury, Hanna Jean

    Expert review of anticancer therapy

    2014  Volume 14, Issue 7, Page(s) 765–770

    Abstract: Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). ... ...

    Abstract Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.
    MeSH term(s) Aniline Compounds/adverse effects ; Aniline Compounds/pharmacokinetics ; Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Drug Approval ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Molecular Targeted Therapy ; Nitriles/adverse effects ; Nitriles/pharmacokinetics ; Nitriles/pharmacology ; Nitriles/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-abl/genetics ; Quinolines/adverse effects ; Quinolines/pharmacokinetics ; Quinolines/pharmacology ; Quinolines/therapeutic use ; United States ; United States Food and Drug Administration
    Chemical Substances Aniline Compounds ; Nitriles ; Protein Kinase Inhibitors ; Quinolines ; bosutinib (5018V4AEZ0) ; Proto-Oncogene Proteins c-abl (EC 2.7.10.2)
    Language English
    Publishing date 2014-07
    Publishing country England
    Document type Journal Article
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1586/14737140.2014.924400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia.

    Hill, Brittany G / Shen, Ann Qi / El Rassi, Fuad / Khoury, Hanna Jean

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2016  Volume 34, Issue 8, Page(s) e68–9

    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Blast Crisis/pathology ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Leukemia, Myeloid, Chronic-Phase/enzymology ; Leukemia, Myeloid, Chronic-Phase/pathology ; Protein Kinase Inhibitors/administration & dosage ; Remission Induction
    Chemical Substances Protein Kinase Inhibitors
    Language English
    Publishing date 2016-03-10
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2013.50.1221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.

    Kong, Jee Hyun / Winton, Elliott F / Heffner, Leonard T / Gaddh, Manila / Hill, Brittany / Neely, Jessica / Hatcher, Angela / Joseph, Meena / Arellano, Martha / El-Rassi, Fuad / Kim, Audrey / Khoury, Jean Hanna / Kota, Vamsi K

    Journal of clinical medicine

    2020  Volume 9, Issue 5

    Abstract: We sought to evaluate the outcomes of chronic phase (CP) chronic myeloid leukemia (CML) in an era where five tyrosine kinase inhibitors (TKIs) are commercially available for the treatment of CML. Records of patients diagnosed with CP CML, treated with ... ...

    Abstract We sought to evaluate the outcomes of chronic phase (CP) chronic myeloid leukemia (CML) in an era where five tyrosine kinase inhibitors (TKIs) are commercially available for the treatment of CML. Records of patients diagnosed with CP CML, treated with TKIs and referred to our center were reviewed. Between January 2005 and April 2016, 206 patients were followed for a median of 48.8 (1.4-190.1) months. A total of 76 (37%) patients received one TKI, 73 (35%) received two TKIs and 57 (28%) were exposed to >3 TKIs (3 TKIs,
    Language English
    Publishing date 2020-05-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9051542
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

    Shen, Ann Q / Wilson, Nicole M / Gleason, Shannon L / Khoury, Hanna Jean

    Therapeutic advances in hematology

    2014  Volume 5, Issue 1, Page(s) 13–17

    Abstract: Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that ... ...

    Abstract Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview of bosutinib, covering pharmacodynamics and pharmacokinetic properties, results of treatment in newly diagnosed and previously treated chronic myeloid leukemia patients, as well as common side effects.
    Language English
    Publishing date 2014-01-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2585183-4
    ISSN 2040-6215 ; 2040-6207
    ISSN (online) 2040-6215
    ISSN 2040-6207
    DOI 10.1177/2040620713510481
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Bosutinib treatment for Philadelphia chromosome-positive leukemias.

    Bethelmie-Bryan, Beverly / Lord, Katharine / Holloway, Stacie / Khoury, Hanna Jean

    Future oncology (London, England)

    2014  Volume 10, Issue 2, Page(s) 179–185

    Abstract: The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that ... ...

    Abstract The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that do not harbor the T315I or V299L ABL kinase domain mutations. Bosutinib is overall well tolerated; transient diarrhea is the most common side effect. This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias.
    MeSH term(s) Aniline Compounds/adverse effects ; Aniline Compounds/chemistry ; Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Drug Approval/legislation & jurisprudence ; Humans ; Leukemia/drug therapy ; Leukemia/genetics ; Leukemia/pathology ; Neoplasm Staging ; Nitriles/adverse effects ; Nitriles/chemistry ; Nitriles/pharmacology ; Nitriles/therapeutic use ; Philadelphia Chromosome ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Quinolines/adverse effects ; Quinolines/chemistry ; Quinolines/pharmacology ; Quinolines/therapeutic use ; Treatment Outcome
    Chemical Substances Aniline Compounds ; Antineoplastic Agents ; Nitriles ; Protein Kinase Inhibitors ; Quinolines ; bosutinib (5018V4AEZ0)
    Language English
    Publishing date 2014-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2184533-5
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon.13.268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top